In a double-blind, placebo controlled two-month crossover study with overweight but not obese volunteers, subjects took two tablets per meal; half taking a placebo, half taking FBCx. They were instructed not to change their eating or activity programs.
It has previously been reported that early intervention with FBCx has beneficial effects on weight management, and that in animal studies it may preferentially reduce blood levels of saturated and trans-fats. This investigation involves overweight but not obese individuals and was intended to confirm the effects of FBCx on both weight and blood lipid management.
In 28 compliant participants, when the active phase was compared to the control phase, there were significant beneficial effects on body weight, lipid profile and low density lipoprotein cholesterol (LDL-C). Positive, but not statistically significant effects were also observed on apolipoprotein (ApoB) and insulin levels.
Supplementation of 6 g/day of FBCx (2 g within an hour of each fat-containing meal for 30 days), without any diet or lifestyle changes, supported both healthy weight and blood lipids.
REFERENCE: Comerford KB, Artiss JD, Jen KL, Karakas SE. The beneficial effects of α-cyclodextrin on blood lipids and weight loss in healthy humans. Obesity (Silver Spring). 2011 Jun;19(6):1200-4. doi: 10.1038/oby.2010.280. Epub 2010 Dec 2.